...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: There was once value here

I used to think Zenith held a lot of potential value.  It looks to me now that this is just being played out.  Still likely has more value than RVX, but I Have no idea how this management group could possibly raise enough $ to get serious trials going.  This should be sold for whatever they can get....and it is unlikely to be much.

 

I've made other bad investments but this is right up there (along with RVX).  I stopped following RVX a while back...If I ever get anything for my Zenith shares I will be surprised.

 

Good luck to all.

 

Share
New Message
Please login to post a reply